Dassault Systèmes has released three industry solution experiences for life sciences, pharmaceutical and biotechnology companies to enable them to design, develop and produce new therapeutics.
Designed to complement the existing ‘Licence to Cure for BioPharma’ compliance solution, the new ‘ONE Lab’, ‘Designed to Cure’ and ‘Made to Cure for BioPharma’ solution experiences will help pharmaceutical and biotechnology companies streamline the scientific and operational processes involved in therapeutics innovation.
Together, they allow for biological and chemical modelling and simulation, open collaborative discovery and research, unified laboratory management, efficient production processes and integrated quality and regulatory management. These are all critical capabilities for bringing effective patient therapies to market faster and at lower costs.
“Dassault Systèmes’ industry solution experiences for life sciences leverage the same 3DEXPERIENCE universes that have long been used by the industrial engineering world to enhance consumer experiences,” said Jean Colombel, vice president of Life Sciences Industry at Dassault Systèmes. “In life sciences, we focus on the patient experience. With a digital environment, companies can maximise return on investment, accelerate decision making, bring advanced solutions to market faster and potentially change lives.”
‘ONE Lab’ integrates people, resources, processes, data, analysis and documentation so that laboratories can collaborate on researching, developing and testing products.
Meanwhile, ‘Made to Cure for BioPharma’ allows companies to collect process and quality data from multiple organisations to optimise products, while reducing process development times and technology transfer costs.
‘Designed to Cure’ uses collaboration, predictive analytics and virtual design and simulation to model and identify higher quality candidates earlier in the process.
Share this story